Zanaflex Tablet
Product Images NDC 70515-594

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 70515-594). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Covis Pharma Us, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure of tizanidine hydrochloride, the active ingredient in Zanaflex capsules. The diagram shows the molecular arrangement including a chlorinated aromatic ring and a thiazole ring structure with associated atoms and bonds.*

FDA Label Image

Figure 1 (Image 02)

A pharmacokinetic line graph showing plasma tizanidine concentration (ng/mL) over time (hours from dosing) for 4 mg tizanidine tablets and capsules taken with and without food. The graph illustrates concentration changes from 0 to 24 hours post-dose for four conditions: tablets with food, tablets without food, capsules with food, and capsules without food.*

FDA Label Image

Figure 2 (Image 03)

A line graph depicting improvement in Ashworth Score over 6 hours post-dose for tizanidine hydrochloride at 8 mg and 16 mg doses compared to placebo. The x-axis represents hours after dosing, and the y-axis shows improvement in Ashworth Score, with error bars indicating variability.*

FDA Label Image

Figure 3 (Image 04)

A graph showing improvement in Ashworth Score over time with tizanidine versus placebo. The x-axis displays three time points: End of Titration (Study Week 3), End of Maintenance, and Endpoint (Last Observation). The y-axis shows improvement in Ashworth Score, with negative values indicating improvement. Data points for tizanidine at a mean dose of 28.8 mg are represented by squares with error bars, showing consistent improvement, while placebo data points are shown as circles with smaller improvements.*

FDA Label Image

Principal Display Panel (2 mg Capsule Bottle)

Zanaflex 2 mg capsules label showing tizanidine hydrochloride as the active ingredient. The label indicates 150 capsules in the package, manufactured for Covis Pharma with storage and safety instructions. It contains a barcode, NDC 70515-602-15, and a warning that the product is not interchangeable with tizanidine tablets or other Zanaflex tablets.*

FDA Label Image

Principal Display Panel (4 mg Capsule Bottle)

Zanaflex capsules label showing 4 mg strength of tizanidine hydrochloride, with 150 capsules in the package. Label includes instructions for storage, child-resistant closure warning, and a stop symbol indicating these capsules are not interchangeable with tizanidine tablets. Manufactured for Covis Pharma US, Inc, with an NDC of 70515-604-15.*

FDA Label Image

Principal Display Panel (6 mg Capsule Bottle)

Label for Zanaflex Capsules containing tizanidine hydrochloride, 6 mg strength. The label indicates a package size of 150 capsules and highlights that each capsule contains 6.87 mg tizanidine hydrochloride, equivalent to 6 mg tizanidine base. It is manufactured for Covis Pharma US, Inc. Storage instructions and safety warnings are also present, including a notice that the capsules are not interchangeable with tablets of the same ingredient.*

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle)

Label for Zanaflex 4 mg capsules containing tizanidine hydrochloride, manufactured by Covis Pharma US, Inc. The label indicates a package size of 150 tablets, includes a STOP warning that Zanaflex tablets are not interchangeable with Zanaflex capsules, and provides prescribing information and storage instructions. The label also displays the NDC number 70515-594-15 and includes a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.